Alpine Immune Sciences Announces Preclinical Data from ALPN-101 Program Demonstrating Efficacy in Humanized Model of Graft Versus Host Disease
(World News Science)

- Data Presented at 59 American Society of Hematology Annual Meeting & Exposition - SEATTLE, December 9, 2017 - Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced results from a preclinical study of the company`s ALPN-101 program in a humanized model of graft vs. host disease (GvHD). Results showed Alpine`s ICOSL vIgD-Fc fusion proteins demonstrated therapeutic efficacy, including suppressing an allogeneic immune response in vitro, improving survival, and reducing GvHD disease activity. The data were presented in a poster session, titled `Experimental Transplantation:...